The United States of America, As Represented by the Secretary, Department of Health and Human Services

Columbia University

Vanderbilt University

The United States of America, As Represented by the Secretary, Departmen

Ivelin Georgiev

Baoshan Zhang

Yongping Yang

Peter D Kwong

John R Mascola

Michael Gordon Joyce

Gwo-Yu Chuang

Tongqing Zhou

Guillaume Stewart-Jones

Marie Pancera

Barney S Graham

Mark Connors

Aliaksandr Druz

Gilad Ofek

Mallika Sastry

Gary J Nabel

Man Chen

Jason Gorman

Ulrich Baxa

Cinque Soto

Rebecca S Rudicell

Jiang Zhu

Masaru Kanekiyo

Cheng Cheng

Jeffrey C Boyington

Young Do Kwon

Yaroslav Tsybovsky

Joseph Van Galen

John Mascola

Zhi-yong Yang

Jason Scott McLellan

Wing-Pui Kong

Wei Shi

Xueling Wu

Li Ou

Jinghe Huang

Paul Thomas

Leo Laub

Lei Chen

Sanjay Srivatsan

Emily Rundlet

Rita Chen

Priyamvada Acharya

Richard Schwartz

Syed M Moin

Lawrence Shapiro

Jonathan Cooper

Mangaiarkarasi Asokan

Michael Bender

Mark Louder

Lisa Kueltzo

Robert Bailer

Sijy O'Dell

Amarendra Pegu

Krisha McKee

Kevin Carlton

Tatyana Gindin

Zhi-Yong Yang

Rebecca M Lynch

Marion Francis Setliff

Andrea Shiakolas

Kelsey Pilewski

Kevin J Kramer

Rohit Venkat

Rebecca Lynch

Leo B Laub

The present disclosure relates to high-throughput systems and methods for the detection of ligand-blocking antibodies and for determining antibody potency.

Methods for identification of ligand-blocking antibodies and for determining antibody potency

The present disclosure relates to antibodies and uses thereof for treating lung cancer.

Therapeutic antibodies for treating lung cancer

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Self-assembling insect ferritin nanoparticles

Neutralizing antibodies to HIV-1 GP41 and their use

Substitutions-modified prefusion RSV F proteins and their use

Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens

Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.

Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

Growing community of inventors

Nashville, TN, United States of America

Ivelin Georgiev